Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) reported that on July 31, 2026, its Board Compensation Committee granted inducement stock options to three new employees to purchase an aggregate of 30,800 shares of common stock at an exercise price of $10.01 per share.
According to Candel Therapeutics, the awards were granted under the 2025 Inducement Plan, adopted on December 24, 2025, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). Vesting covers 25% of shares on the first employment anniversary and the remaining 75% in 36 equal monthly installments, subject to continued service.
Positive
- None.
Negative
- None.
News Explained
This is an option grant, not a reported share issuance: it gives three new employees rights to purchase 30,800 common shares, while any ownership dilution would depend on a later exercise and share issuance.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 08 | Inducement grant | Neutral | +0.1% | Stock option inducement award for new Chief Commercial Officer |
| Jul 01 | Inducement grant | Neutral | -0.5% | Inducement stock option granted to one new employee |
| Jun 30 | Clinical trial initiation | Positive | -0.6% | Global pivotal Phase 3 AURORA trial initiated in advanced NSCLC |
| Jun 25 | Executive appointment | Positive | +2.2% | Mark Sims appointed Chief Commercial Officer effective July 6 |
| Jun 02 | Phase 3 data publication | Positive | -1.1% | Phase 3 prostate cancer data showed improved disease-free survival |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent inducement-grant announcements produced near-flat reactions, while several positive clinical announcements diverged from the stock's price reaction.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
